Cancer/ ESMO2016/ R&D Cancer market commentary: Roche’s Tecentriq muscles into NSCLC Andrew McConaghie BMS, breakthrough, cancer, docetaxel, ESMO, kantar, Keytruda, Merck, Opdivo, Roche, Tecentriq, trial 0 Comment Roche’s PD-L1 drug has generated impressive data in second line lung cancer Share X Cancer market commentary: Roche’s Tecentriq muscles into NSCLC https://pharmaphorum.com/esmo-2016/cancer-market-commentary-roches-tecentriq-muscles-nsclc/
Cancer/ ESMO2016/ R&D/ Views and analysis Eye on ESMO: Day 2 – gamechangers take centre stage Andrew McConaghie breakthrough, clinical trial, ESMO, Lilly, Oncology, ovarian, pharma, trial 0 Comment Novartis’ phase 3 advanced breast cancer therapy ribociclib shows promise Share X Eye on ESMO: Day 2 – gamechangers take centre stage https://pharmaphorum.com/esmo-2016/eye-esmo-day-two-gamechangers-take-centre-stage/
Clinical/ Oncology/ Partner Content/ Press releases/ Quintiles/ Quintiles - ContentIO VIDEO: Immunotherapy monitoring: Is Immuno-PET the solution? Adam Jeffery biopsy, cancer, clinical trial, image modality, immuno-oncology, immunotherapy, monitoring, pharma, quintiles, trial 0 Comment The rapid advancement of immunotherapy in recent years has presented a number of challenges to pharmaceutical firms looking Share X VIDEO: Immunotherapy monitoring: Is Immuno-PET the solution? https://pharmaphorum.com/partner-content-oncology/immuno-pet-offer-solution-effective-immunotherapy-monitoring/